<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The management of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in elderly patients is a significant clinical problem </plain></SENT>
<SENT sid="1" pm="."><plain>The therapeutic options range from observation alone for patients with low-risk disease, lenalidomide for patients with <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q-syndrome</z:e>, to <z:chebi fb="0" ids="2038">5-azacytidine</z:chebi> (5-AZA) for patients with higher risk of disease </plain></SENT>
<SENT sid="2" pm="."><plain>In this paper, we summarize the clinical course of three patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treated with 5-AZA as well as the management and supportive care measures for adverse events </plain></SENT>
<SENT sid="3" pm="."><plain>As expected, based on available clinical trials data, the agent resulted in clinical and hematological improvement in these patients with acceptable side effects </plain></SENT>
<SENT sid="4" pm="."><plain>5-AZA is an attractive option for elderly patients with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>